The present disclosure provides a neutron capture therapy system for eliminating amyloid -protein deposition plaque, comprising a neutron capture therapy device and a .sup.10B-containing compound capable of specifically binding to amyloid -protein deposition plaque, and the energy generated when the neutron beam generated by the neutron capture therapy device irradiates on the .sup.10B element can destroy the structure of the amyloid -protein deposition plaque. The beneficial effects of the present disclosure are targeted and highly effective destruction of amyloid -protein deposition plaque.

Disclosed herein are methods, processes, devices, and compositions for the treatment of target cells and/or tissues, the treatment comprising identifying the target cell with positron emission tomography and then directing a epithermal neutron toward the identified target cell. In various aspects, the target cells and/or tissues take up and metabolize boronated glucose and radioactive fluorinated glucose molecules.

A neutron capture therapy system capable of eliminating amyloid -protein includes a neutron capture therapy device and a compound capable of specifically binding to the amyloid -protein having a nuclide with a large thermal neutron capture cross section. The neutron capture therapy device includes a neutron source, a beam shaping assembly and a collimator, the neutrons released by the neutron source pass through the beam shaping assembly and are slowed into a neutron beam within a certain energy range. The neutron beam irradiates the compound, and the energy generated by the reaction thereof can destroy the structure of the amyloid -protein. The neutron capture therapy system can specifically eliminate the amyloid -protein, and reduce the damage to the tissues surrounding the amyloid -protein.

Provided are a surface-modified nanoparticle that can be easily produced and can selectively deliver boron atoms into cancer cells and maintain the boron atoms, and a method for producing the surface-modified nanoparticle. The surface-modified nanoparticle of the present disclosure includes a nanocarbon material, and a surface-modifying group of the nanocarbon material, and has a group containing a boron atom as the surface-modifying group.

A boron neutron capture therapy system has a neutron beam irradiation device, a patient restraint/placement portion, a three-dimensional diagnostic device, an irradiation table, a position adjustment mechanism, and a control unit. The boron neutron capture therapy system performs position determination with a sufficient degree of accuracy at the time of the boron neutron capture therapy. Further, the control unit, using the movement of the irradiation table, performs collision avoidance processing that changes the movement of the irradiation table before the patient restrained on the patient restraint/placement portion receives injury by colliding with the irradiation port, and thus, collision between the patient and the irradiation port can be avoided.

Provided is a compound for specifically binding to amyloid -protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid -protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid -protein. Similarly, when the compound is labelled with radioactive element .sup.11C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid -protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid -protein.

The present disclosure provides a lyophilized powder containing a boron complex. The lyophilized powder includes a sugar acid and a complex formed by a dehydration condensation reaction of a dihydroxyboryl compound and a sugar or a sugar alcohol. The present disclosure also provides a method of forming a lyophilized powder containing a boron complex. The method includes the following operations. A dihydroxyboryl compound and a sugar or a sugar alcohol are mixed to form a mixture, and the mixture includes a complex formed by a dehydration condensation reaction of the dihydroxyboryl compound and the sugar or the sugar alcohol. The mixture is immersed in liquid nitrogen to freeze the mixture to form a pre-frozen body. A vacuum drying process is performed to evaporate water of the pre-frozen body to form a lyophilized powder.

Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (MMP) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described. ##STR00001##

Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6.

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.